A Study of RO4917838 (Bitopertin) in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (WN25309)
Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
This multi-center, randomized, double blind, parallel-group, placebo-controlled study will
evaluate the efficacy and safety of RO4917838 (bitopertin) in patients with persistent,
predominant negative symptoms of schizophrenia. Patients, on stable treatment with
antipsychotics, will be randomized to receive daily oral doses of RO4917838 or matching
placebo for 52 weeks, followed by an optional treatment extension for up to 3 years.